Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia

Ann Hematol. 2014 Aug;93(8):1441-2. doi: 10.1007/s00277-013-1985-9. Epub 2013 Dec 12.

Authors

Yi-Yang Chen¹, Cih-En Huang, Hui-Ju Chou, Pei-Shan Tsai, Chang-Hsien Lu, Miao-Fen Chen, Kuan-Der Lee, Ping-Tsung Chen, Jrhau Lung, Chih-Cheng Chen

Affiliation

¹ Division of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.

PMID: 24337413
DOI: 10.1007/s00277-013-1985-9

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Brain / pathology*
Clone Cells / drug effects
Cytarabine / administration & dosage
DNA (Cytosine-5-)-Methyltransferases / genetics*
DNA (Cytosine-5-)-Methyltransferases / physiology
DNA Methyltransferase 3A
DNA, Neoplasm / cerebrospinal fluid
DNA, Neoplasm / genetics
Daunorubicin / administration & dosage
Drug Resistance, Neoplasm / genetics*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / pathology
Leukemic Infiltration*
Middle Aged
Neoplasm Proteins / genetics*
Neoplasm Proteins / physiology
Neoplastic Stem Cells / drug effects
Prognosis
Risk

Substances

DNA, Neoplasm
DNMT3A protein, human
Neoplasm Proteins
Cytarabine
DNA (Cytosine-5-)-Methyltransferases
DNA Methyltransferase 3A
Daunorubicin